Compare Sana Biotechnology Inc (SANA) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Smith & Nephew plc — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Smith & Nephew plc trades at $30.45 (market cap $12.64B). The key difference: Smith & Nephew plc is far larger — about 14.5× Sana Biotechnology Inc's market cap, and Smith & Nephew plc pays a 2.57% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | SNN | |
|---|---|---|
Market Cap | $873.84M | $12.64B |
Sector | Health | Health |
52-Week High | $5.92 | $38.70 |
52-Week Low | $2.68 | $28.73 |
Enterprise Value | $848.03M | $15.41B |
Dividend Yield | — | 2.57% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
